SCHEMBL10185209

SCHEMBL10185209

Cc1cnc2cnc(C(=O)O)cn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.39
HCAR2 Q8TDS4 2/20 0.39
GAA P10253 3/20 0.38
P4HTM Q9NXG6 4/20 0.36
P4HA1 P13674 1/20 0.36
MIF P14174 1/20 0.36
ALDH1A1 P00352 4/20 0.36
PKM P14618 2/20 0.36
TGFBR1 P36897 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 1/20 0.34
POLB P06746 1/20 0.34
APOBEC3A P31941 1/20 0.34
ASPH Q12797 1/20 0.33
KDM8 Q8N371 1/20 0.33
NAPRT Q6XQN6 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24998121 0.79 P4HTM (0.34) KDM4EHCAR2GAAP4HTMP4HA1
SCHEMBL10185177 0.79 KDM4E (0.43) KDM4EHCAR2P4HTMP4HA1MIF
SCHEMBL10235699 0.75 ASPH (0.41) KDM4EGAAP4HTMP4HA1MIF
SCHEMBL21816422 0.74 KDM4E (0.49) KDM4EGAAP4HTMP4HA1MIF
SCHEMBL31244546 0.73 KDM4E (0.41) KDM4EHCAR2GAAP4HTMP4HA1
SCHEMBL10185246 0.73 KDM4E (0.41) KDM4EHCAR2GAAP4HTMP4HA1
SCHEMBL13436502 0.72 TGFBR1 (0.43) KDM4EALDH1A1TGFBR1LMNACYP1A2
SCHEMBL38656483 0.70 KDM4E (0.52) KDM4E
SCHEMBL119926 0.70 GAA (0.66) KDM4EGAAALDH1A1L3MBTL1LMNA
SCHEMBL25418147 0.70 KDM4E (0.44) KDM4EHCAR2P4HTMP4HA1MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF KDM4E 2722/4885HCAR2 3509/4885GAA 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.